medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2011, Número 1

<< Anterior Siguiente >>

Rev Biomed 2011; 22 (1)


Detección y tipificación de papilomavirus humano en lesiones condilomatosas anogenitales de hombres cubanos seropositivos al VIH-1

Blanco-González OA, Soto-Brito Y, Blanco-González B, Acosta-Tabares S, Capó PV, Toledo ME

Idioma: Español
Referencias bibliográficas: 44
Paginas: 21-30
Archivo PDF: 234.25 Kb.


RESUMEN

Introducción. Los condilomas son causados por Papilomavirus Humano (PVH), esencialmente tipos 6 y 11. No se conoce la prevalencia de PVH en hombres cubanos seropositivos al Virus de la Inmunodeficiencia Humana (VIH).
Objetivo. Detectar infección por PVH, genotipos y aspectos clínicos en hombres cubanos seropositivos al VIH-1.
Materiales y Métodos. Se estudiaron muestras de condilomas en 30 pacientes cubanos atendidos en el Instituto “Pedro Kourí”. Al tejido se le realizó análisis histopatológico y detección de PVH mediante Reacción en Cadena de la Polimerasa (RCP) con oligos MY09/11. Además, genotipificación con 32 sondas biotinadas, para PVH de alto o bajo riesgo oncogénico.
Resultados. El ADN de PVH fue detectado en 100% de las muestras. Los genotipos 6 y 11 se identificaron en 63.3% y en 53.3% de los casos, respectivamente. En 19 individuos, se demostró coinfección con genotipos de bajo y alto riesgo. En un mismo paciente se pudieron detectar hasta 11 genotipos, con predominio de PVH 16 (50%) y 18 (43.3%). La terapia más usada fue el ácido tricloracético. Se observó asociación estadística [X2 =11.27; RR=28.5; 95%IC: 2.6-306.6 (p=0.008)] entre la presencia de genotipos de alto riesgo oncogénico y el conteo de linfocitos T CD4+‹500 células /mm3.
Conclusiones. La detección de PVH de alto y bajo riesgo oncogénico, en lesiones condilomatosas de pacientes cubanos seropositivos al VIH-1, en relación con el conteo de CD4+ es un hallazgo de interés para el seguimiento y la detección temprana de neoplasias anogenitales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23(17):2337-45.

  2. Soto Y. Papovavirus. En: Llop A, Valdés-Dapena MM, Zuazo JL, editores. Microbiolgía y Parasitología Médica. Ciudad de La Habana: Editorial Ciencias Médicas; 2001.p. 60-5.

  3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1):12-9.

  4. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 2003; 95(6):E2.

  5. McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses. Virus Res 2009; 143(2):195-208.

  6. de Villiers EM, Gunst K. Characterization of seven novel human papillomavirus types isolated from cutaneous tissue, but also present in mucosal lesions. J Gen Virol 2009; 90(Pt 8):1999-2004

  7. Arora R, Kumar A, Prusty BK, Kailash U, Batra S, Das BC. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur J Obstet Gynecol Reprod Biol 2005; 121(1):104-9.

  8. Chopra KF, Tyring SK. The impact of the human inmmunodeficiency virus on the human papillomavirus epidemic. Aech Dermatol 1997; 133(5):629-33.

  9. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human inmmunodeficiency virus infection and acquired inmmunodeficiency syndrome. J Natl Cancer Inst 2000; 92(18):1500-10.

  10. Kiyofumi E. HPV-associated cutaneous lesions. Uirusu 2008; 58(2):173-82.

  11. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 2004; 193(1):35-44.

  12. Bauer HM, Greer CF, Manos MM. Determination of genital human papillomavirus infection using consensus PCR. En: Herrington CS, McGee JOD, editors. Diagnostic molecular pathology: a practical approach. Oxford, United Kingdom: Oxford University Press; 1992. p. 132-52.

  13. Gravitt PE, Manos MM. Polymerase chain reactionbased methods for the detection of human papillomavirus DNA. IARC Sci Publ 1992; 119:121-33.

  14. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papilloma virus infection in human inmmunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91(3):226-36.

  15. Tham KM, Chow VT, Singh P, Tock EP, Ching KC, Lim-Tan SK, et al. Diagnostic sensitivity of polymerase chain reaction and Southern blot hybridization for the detection of human papillomavirus DNA in biopsy specimens from cervical lesions. Am J Clin Pathol 1991; 95(5):638-46.

  16. Zur Hausen H. Papillomaviruses--to vaccination and beyond. Biochemistry 2008; 73(5):498-503.

  17. Bouwes Bavinck JN. Epidemiological aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Hum Exp Toxicol 1995; 14(1):98.

  18. Bachmeyer C, Orlandin V, Grimaldi D, Bonnard P, Moguelet P, Aractingi S. Skin lesions as another possible clinical manifestation of mitochondrial toxicity in an HIV-infected patient. Dermatology 2007; 214(2):189-90.

  19. Potthoff A, Brockmeyer NH. HIV-associated Kaposi sarcoma: pathogenesis and therapy. J Dtsch Dermatol Ges 2007; 5(12):1091-4.

  20. Stier EA, Baranoski AS. Human papillomavirusrelated diseases in HIV-infected individuals. Curr Opin Oncol 2008; 20(5):541-6.

  21. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human inmmunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183(3):383-91.

  22. Palefsky JM. Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol 2009; 21(5):433-8

  23. Hong SL, Wang JB, Liu YH, Si JY, Xu XM, Guo XC, et al. Identification and assessment of multiple human papillomavirus types in condyloma acuminata lesions from patients with genital warts in Beijing area. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2002; 24(4):397-400.

  24. Dupin N. Genital warts. Clin Dermatol 2004; 22(6):481-6.

  25. Corbalan-Velez R, Ruiz-Macia JA, Brufan C, Carapeto FJ. Cutaneous squamous cell carcinoma and human papillomavirus. Actas Dermosifiliogr 2007; 98(9):583-93.

  26. Sexually trasmitted dideases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51(RR-6):1-78.

  27. Ekstrom J, Foeslund O, Dillner J. Three novel papillomaviruses (HPV109,HPV112 and HPV114) and their presence in cutaneous and mucosal samples. Virology 2010; 397(2):331-6.

  28. Shimizu M, Adachi A, Zheng S, Matsunaga J, Kusakari Y, Tagami H, et al. Detection of various types of human papillomavirus DNA, mainly belonging to the cutaneous-group, more frequently in normal tissue than in squamous cell carcinomas of the lip. J Dermatol Sci 2004; 36(1):33-9.

  29. Ljubojevic S, Lipozencic J, Skerlev M, Zele-Starcevic L, Ljubojevic N, Babic D, et al. Diagnostic-therapeutic guidelines for men whose partners have HPV genital infection. Lijec Vjesn 2009; 131(9-10):269-74.

  30. Arany I, Tyring SK. Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS 1998; 9(5):268-71.

  31. Hessol NA, Holly EA, Efird JT, Minkoff H, Schowalter K, Darragh TM, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23(1):59-70.

  32. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12(5-6):291-307.

  33. O´Mahony C. Genital warts: current and future management options. Am J Clin Dermantol 2005; 6(4):239-43.

  34. Steinberg JL, Cibley LJ, Rice PA. Genital warts: diagnosis, treatment, and counseling for the patient. Curr Clin Top Infect Dis 1993; 13:99-122.

  35. Slade HB, Owens ML,Tomai MA, Miller RL.Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs 1998; 7(3):437-49.

  36. Hober D, Ajram L, Chehadeh W, Lazrek M, Goffard A, Dewilde A, et al. Mechanisms of imiquimod indirect antiviral activity. Ann Biol Clin 2005; 63(2):155-63.

  37. Matezak E. Human papillomavirus infection: an emerging problem in anal and other squamous cell cancers. Gastroenterology 2001; 120(4):1046-8.

  38. Sobhani I, Vuagnat A, Walker F, Vissuzaine C, Mirin B, Hervatin F, et al. Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology 2001; 120(4):857-66.

  39. Stanley MA, Immune responses to human papilloma viruses. Indian J Med Res 2009; 130(3):266-76.

  40. Georgieva S, Iordanov V, Sergieva S. Nature of cervical cancer and other HPV - associated cancers. J BUON 2009; 14(3):391-8.




2020     |     www.medigraphic.com